Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV
7 affiliations
- 1Division of Clinical Pharmacology, Department of Medicine Stellenbosch University Cape Town South Africa
- 2Department of Clinical Pharmacology and Therapeutics Gombe State University Gombe Nigeria
- 3HIV Mental Health Research Unit, Department of Psychiatry and Mental Health University of Cape Town Cape Town South Africa
- 4Imperial College Healthcare NHS Trust London UK
- 5Pharmacology and Therapeutics University of Liverpool Liverpool UK
- 6School of Pharmacy University College London London UK
- 7Certara Radnor Pennsylvania USA
Abstract
Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking. This study characterizes dolutegravir pharmacokinetics in plasma and cerebrospinal fluid to describe the plasma‐to‐cerebrospinal fluid equilibration rate constant and cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient. Sparse pharmacokinetics samples were collected from 121 antiretroviral therapy‐experienced adults who are predominantly overweight or obese (body mass index: 32.2 ± 8.7 kg/m2) receiving daily dolutegravir (50 mg)‐based therapy. The model was developed using nonlinear mixed‐effects modeling in NONMEM. Plasma dolutegravir pharmacokinetics were best described by a one‐compartment model with first‐order absorption and elimination. The population estimate for apparent oral clearance was 1.38 L/h/70 kg. Cerebrospinal fluid data were modeled using a sequential approach with a hypothetical effect compartment linked to plasma to estimate equilibration kinetics and relative cerebrospinal fluid exposure at steady‐state. Key cerebrospinal fluid penetration parameters included a plasma‐to‐cerebrospinal fluid equilibration rate constant of 0.38 h−1, corresponding to an equilibration half‐life of 1.82 h, and a cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient of 0.0015, indicating 0.15% cerebrospinal fluid penetration relative to plasma. Post hoc estimated area under the concentration‐time curve (0–24) demonstrated a moderate inverse correlation with body mass index (r = −0.34), indicating that dolutegravir exposure decreases with increasing body mass index. The model revealed rapid plasma‐to‐cerebrospinal fluid equilibration kinetics with low steady‐state cerebrospinal fluid penetration in this predominantly overweight and obese population.
Related
- Pharmacokinetics and safety of dolutegravir in term neonates exposed to HIV-1 (IMPAACT 2023): a phase 1, open-label, multicentre study
- Mechanistic Population Pharmacokinetic Modeling of Extended-Release Metformin in Obese South African Women Living with HIV on Dolutegravir.
- Comparative Detection of IDH1 R132H and TERT Promoter Mutations in Plasma and Cerebrospinal Fluid of Patients with Glioma Using Targeted Droplet Digital PCR
- Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
BibTeX
@article{ali2026population,
title = {{Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV}},
author = {Mohammed W. Ali and Sam Nightingale and Tracy Kellermann and John Joska and Alan Winston and Saye Khoo and Joseph F. Standing and Eric H. Decloedt and Ahmed A. Abulfathi},
journal = {CPT: Pharmacometrics \& Systems Pharmacology},
year = {2026},
month = sep,
doi = {10.1002/psp4.70345},
url = {https://doi.org/10.1002/psp4.70345},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV
AU - Mohammed W. Ali
AU - Sam Nightingale
AU - Tracy Kellermann
AU - John Joska
AU - Alan Winston
AU - Saye Khoo
AU - Joseph F. Standing
AU - Eric H. Decloedt
AU - Ahmed A. Abulfathi
PY - 2026
DA - 2026/09/29
JO - CPT: Pharmacometrics & Systems Pharmacology
DO - 10.1002/psp4.70345
UR - https://doi.org/10.1002/psp4.70345
AB - Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking. This study characterizes dolutegravir pharmacokinetics in plasma and cerebrospinal fluid to describe the plasma‐to‐cerebrospinal fluid equilibration rate constant and cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient. Sparse pharmacokinetics samples were collected from 121 antiretroviral therapy‐experienced adults who are predominantly overweight or obese (body mass index: 32.2 ± 8.7 kg/m2) receiving daily dolutegravir (50 mg)‐based therapy. The model was developed using nonlinear mixed‐effects modeling in NONMEM. Plasma dolutegravir pharmacokinetics were best described by a one‐compartment model with first‐order absorption and elimination. The population estimate for apparent oral clearance was 1.38 L/h/70 kg. Cerebrospinal fluid data were modeled using a sequential approach with a hypothetical effect compartment linked to plasma to estimate equilibration kinetics and relative cerebrospinal fluid exposure at steady‐state. Key cerebrospinal fluid penetration parameters included a plasma‐to‐cerebrospinal fluid equilibration rate constant of 0.38 h−1, corresponding to an equilibration half‐life of 1.82 h, and a cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient of 0.0015, indicating 0.15% cerebrospinal fluid penetration relative to plasma. Post hoc estimated area under the concentration‐time curve (0–24) demonstrated a moderate inverse correlation with body mass index (r = −0.34), indicating that dolutegravir exposure decreases with increasing body mass index. The model revealed rapid plasma‐to‐cerebrospinal fluid equilibration kinetics with low steady‐state cerebrospinal fluid penetration in this predominantly overweight and obese population.
SN - 2163-8306
ER -